• Special Issue Topic
    Liquid Biopsy in Thoracic Cancer
    Submission Deadline: May 20, 2020

    Guest Editors

    Dr. Floriana Morgillo E-Mail

    Medical Oncology, Università degli studi della Campania, "L. Vanvitelli", Italy

    Research Keywords: lung cancer; targeted therapy; immunotherapy; translational research; resistance mechnisms

    Dr. Carminia Maria Della Corte E-Mail

    Medical Oncology, Università degli studi della Campania, "L. Vanvitelli", Italy

    About the Special Issue

    “Liquid biopsy” of biological fluids (e.g., plasma and serum, urine, saliva, cerebrospinal fluid, pleural fluid, ascites, stool) is emerging as a powerful tool for non-invasive diagnosis, screening, prognosis, and stratification of cancer patients. This approach is based on the fact that tumor cells release molecules (proteins, DNA, RNA), circulating tumor cells (CTC), and extra cellular vesicles (EV) that can be used as biomarkers.

    Considerable attention has been devoted to the analysis of EGFR mutations in patients with NSCLC, as it is often challenging to obtain tissue biopsies from these patients to help to inform treatment. At present, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) approve the use of information from ctDNA analysis to help to select patients with EGFR-mutant NSCLC for anti-EGFR therapy in the event that a tumour sample is not evaluable. This could offer a pragmatic solution that provides molecular profiling information for patients while avoiding repeat biopsies for some individuals.

    Further studies are ongoing to evaluate the role of this approach for small cell lung cancer and malignant mesothelioma.

    Liquid biopsies may be repeated frequently to provide a more detailed picture of the natural history of the disease with a longitudinal assessment of tumor burden and clues about clonal evolution and emergence of drug- resistant clones leading to clinical relapse, thus implementing our understanding of disease evolution and management.

    Keywords: CTC; early diagnosis; tumor heterogeneity; biomarkers; therapeutic resistance

    Call for Papers

    Published Articles

    Open Access
    Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
    Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small ...
    Giovanni Vicidomini ... Mario Santini
    Online First: October 09, 2020 Explor Target Antitumor Ther. 2020;1:Online First
    DOI: https://doi.org/10.37349/etat.2020.00020
    Times Cited: 0
    Open Access
    Future directions and management of liquid biopsy in non-small cell lung cancer
    Lung cancer represents the world's most common cause of cancer death. In recent years, we moved from a generic therapeutic strategy to a personalized approach, based on the molecular char...
    Alessia Maria Cossu ... Marco Bocchetti
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:239-252
    DOI: https://doi.org/10.37349/etat.2020.00015
    Times Cited: 0
    Open Access
    Circulating cancer stem cells: an interesting niche to explore
    Federica Papaccio
    Published: August 31, 2020 Explor Target Antitumor Ther. 2020;1:253-258
    DOI: https://doi.org/10.37349/etat.2020.00016
    Times Cited: 0
    Open Access
    Role of liquid biopsy for thoracic cancers immunotherapy
    Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the...
    Raimondo Di Liello ... Paloma Martín-Martorell
    Published: June 29, 2020 Explor Target Antitumor Ther 2020;1:183-199
    DOI: https://doi.org/10.37349/etat.2020.00012
    Times Cited: 0